Provided by Tiger Trade Technology Pte. Ltd.

Sutro Biopharma Inc

15.35
-0.6200-3.88%
Post-market: 15.14-0.2100-1.37%19:33 EDT
Volume:371.58K
Turnover:5.69M
Market Cap:254.31M
PE:-0.88
High:16.15
Open:16.15
Low:14.59
Close:15.97
52wk High:43.85
52wk Low:7.15
Shares:16.57M
Float Shares:10.77M
Volume Ratio:1.88
T/O Rate:3.45%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-17.3700
EPS(LYR):-22.4900
ROE:-1810.01%
ROA:-36.08%
PB:-2.46
PE(LYR):-0.68

Loading ...

Analysts Offer Insights on Healthcare Companies: AbSci (ABSI), Summit Therapeutics (SMMT) and Sutro Biopharma (STRO)

TIPRANKS
·
Oct 01

Sutro Biopharma Appoints Lucas Donigian as Senior Vice President, Business Development

GlobeNewswire
·
Sep 29

H.C. Wainwright Sticks to Their Buy Rating for Sutro Biopharma (STRO)

TIPRANKS
·
Sep 22

H.C. Wainwright calls Sutro drop ‘an overreaction’ to limited STRO-004 data

TIPRANKS
·
Aug 17

Analysts Conflicted on These Healthcare Names: Definium Therapeutics (DFTX), Ionis Pharmaceuticals (IONS) and Sutro Biopharma (STRO)

TIPRANKS
·
Aug 15

MacroGenics Q2 Revenue Misses Estimates, Posts Profit on Asset Sale

Reuters
·
Aug 14

Sutro Biopharma Price Target Maintained with a $60.00/Share by Wedbush

Dow Jones
·
Aug 13

Analysts Have Conflicting Sentiments on These Healthcare Companies: Sutro Biopharma (STRO), Summit Therapeutics (SMMT) and Altimmune (ALT)

TIPRANKS
·
Aug 13

Maldonado Reiterates Buy on Sutro, Sees STRO-004 Data as Proof-of-Concept and Keeps $50 Price Target Unchanged

TIPRANKS
·
Aug 13

U.S. Stocks on the MOVE-Sutro Biopharma, Humacyte

Reuters
·
Aug 13

Sutro Biopharma Inc Reports Results for the Quarter Ended June 30 - Earnings Summary

Reuters
·
Aug 12

Sutro Biopharma Tumbles After Missing Estimates

Reuters
·
Aug 12

Sutro Biopharma: Encouraging STRO-004 Early Data and Solid Execution Support Unchanged $54 Price Target and Buy Rating

TIPRANKS
·
Aug 12

Sutro Biopharma Q2 Revenue Misses Estimates, Posts Wider Loss

Reuters
·
Aug 12

Sutro Biopharma Q2 FY26 Net Loss Widens to USD 38.53 Million; Revenue Drops to USD 9.84 Million

Reuters
·
Aug 12

Sutro Biopharma Q2 EPS $(2.33) Misses $(2.19) Estimate, Sales $9.839M Miss $13.048M Estimate

Benzinga Earnings
·
Aug 12

Sutro Biopharma Q2 Revenue USD 9.839 Million Vs. IBES Estimate USD 13 Million

Reuters
·
Aug 12

Sutro Biopharma Q2 EPS USD -2.33

THOMSON REUTERS
·
Aug 12

Sutro Biopharma Inc : Stifel Initiates Coverage with Buy Rating; Price Target $48

THOMSON REUTERS
·
Aug 07

Sutro Biopharma Inc Expected to Post a Loss of $2.22 a Share - Earnings Preview

Reuters
·
Aug 03